{"id":34944,"date":"2025-06-10T12:11:17","date_gmt":"2025-06-10T04:11:17","guid":{"rendered":"https:\/\/flcube.com\/?p=34944"},"modified":"2025-06-10T12:11:18","modified_gmt":"2025-06-10T04:11:18","slug":"huahai-pharma-receives-fda-warning-letter-after-inspection","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=34944","title":{"rendered":"Huahai Pharma Receives FDA Warning Letter After Inspection"},"content":{"rendered":"\n<p>China-based Zhejiang Huahai Pharmaceutical Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/600521:SHA\">SHA: 600521<\/a>) announced that it has received a warning letter from the US Food and Drug Administration (FDA) following an on-site inspection of its Xunqiao Manufacturing Site in Xunqiao Town, Linhai City, conducted from January 16 to January 24, 2025.<\/p>\n\n\n\n<p><strong>FDA Observations and Recommendations<\/strong><br>The FDA&#8217;s letter highlighted observations and improvement recommendations regarding drug products at the Xunqiao Manufacturing Site. Key areas of focus included cleaning management for certain oral solid manufacturing equipment, maintenance of sterile production areas, and the adequacy of parameter studies for tablet rejection during compression.<\/p>\n\n\n\n<p><strong>Company Response<\/strong><br>Huahai Pharma stated that it takes the FDA&#8217;s feedback seriously and has already implemented proactive measures for optimization. The company is maintaining active communication with the FDA to address the concerns raised.<\/p>\n\n\n\n<p><strong>Impact of Warning Letter<\/strong><br>The warning letter will affect the approval of new Abbreviated New Drug Application (ANDA) submissions or supplemental applications related to the Xunqiao Manufacturing Site. Huahai Pharma&#8217;s key manufacturing sites also include its subsidiary Zhejiang Huahai Pharmaceutical Technology Co., Ltd., located in Jiangnan Subdistrict, Linhai City.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/600521_20250610_D4FQ.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600521_20250610_D4FQ.\"><\/object><a id=\"wp-block-file--media-e9be26c3-02c1-49d4-85ed-60ac0b98a3d6\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/600521_20250610_D4FQ.pdf\">600521_20250610_D4FQ<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/600521_20250610_D4FQ.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-e9be26c3-02c1-49d4-85ed-60ac0b98a3d6\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that it has received a warning&#8230;<\/p>\n","protected":false},"author":1,"featured_media":34946,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[31,775,1381],"class_list":["post-34944","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-generic-drugs","tag-huahai-pharmaceutical","tag-sha-600521"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Huahai Pharma Receives FDA Warning Letter After Inspection - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that it has received a warning letter from the US Food and Drug Administration (FDA) following an on-site inspection of its Xunqiao Manufacturing Site in Xunqiao Town, Linhai City, conducted from January 16 to January 24, 2025.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=34944\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Huahai Pharma Receives FDA Warning Letter After Inspection\" \/>\n<meta property=\"og:description\" content=\"China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that it has received a warning letter from the US Food and Drug Administration (FDA) following an on-site inspection of its Xunqiao Manufacturing Site in Xunqiao Town, Linhai City, conducted from January 16 to January 24, 2025.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=34944\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-10T04:11:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-10T04:11:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1001.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34944#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34944\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Huahai Pharma Receives FDA Warning Letter After Inspection\",\"datePublished\":\"2025-06-10T04:11:17+00:00\",\"dateModified\":\"2025-06-10T04:11:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34944\"},\"wordCount\":192,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34944#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1001.webp\",\"keywords\":[\"Generic drugs\",\"Huahai Pharmaceutical\",\"SHA: 600521\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34944#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34944\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=34944\",\"name\":\"Huahai Pharma Receives FDA Warning Letter After Inspection - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34944#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34944#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1001.webp\",\"datePublished\":\"2025-06-10T04:11:17+00:00\",\"dateModified\":\"2025-06-10T04:11:18+00:00\",\"description\":\"China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that it has received a warning letter from the US Food and Drug Administration (FDA) following an on-site inspection of its Xunqiao Manufacturing Site in Xunqiao Town, Linhai City, conducted from January 16 to January 24, 2025.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34944#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34944\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34944#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1001.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1001.webp\",\"width\":1080,\"height\":608,\"caption\":\"Huahai Pharma Receives FDA Warning Letter After Inspection\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34944#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Huahai Pharma Receives FDA Warning Letter After Inspection\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Huahai Pharma Receives FDA Warning Letter After Inspection - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that it has received a warning letter from the US Food and Drug Administration (FDA) following an on-site inspection of its Xunqiao Manufacturing Site in Xunqiao Town, Linhai City, conducted from January 16 to January 24, 2025.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=34944","og_locale":"en_US","og_type":"article","og_title":"Huahai Pharma Receives FDA Warning Letter After Inspection","og_description":"China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that it has received a warning letter from the US Food and Drug Administration (FDA) following an on-site inspection of its Xunqiao Manufacturing Site in Xunqiao Town, Linhai City, conducted from January 16 to January 24, 2025.","og_url":"https:\/\/flcube.com\/?p=34944","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-10T04:11:17+00:00","article_modified_time":"2025-06-10T04:11:18+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1001.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=34944#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=34944"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Huahai Pharma Receives FDA Warning Letter After Inspection","datePublished":"2025-06-10T04:11:17+00:00","dateModified":"2025-06-10T04:11:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=34944"},"wordCount":192,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=34944#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1001.webp","keywords":["Generic drugs","Huahai Pharmaceutical","SHA: 600521"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=34944#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=34944","url":"https:\/\/flcube.com\/?p=34944","name":"Huahai Pharma Receives FDA Warning Letter After Inspection - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=34944#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=34944#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1001.webp","datePublished":"2025-06-10T04:11:17+00:00","dateModified":"2025-06-10T04:11:18+00:00","description":"China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that it has received a warning letter from the US Food and Drug Administration (FDA) following an on-site inspection of its Xunqiao Manufacturing Site in Xunqiao Town, Linhai City, conducted from January 16 to January 24, 2025.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=34944#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=34944"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=34944#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1001.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1001.webp","width":1080,"height":608,"caption":"Huahai Pharma Receives FDA Warning Letter After Inspection"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=34944#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Huahai Pharma Receives FDA Warning Letter After Inspection"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1001.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34944","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34944"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34944\/revisions"}],"predecessor-version":[{"id":34947,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34944\/revisions\/34947"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/34946"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34944"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=34944"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=34944"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}